Agenus, Inc. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 2 PAGES: 76

More Info
									        Agenus, Inc. – Product Pipeline Review – H2 2011
                                                                                          Reference Code: GMDHC01756CDB

                                                                                                 Publication Date: NOV 2011




Agenus, Inc. – Product Pipeline Review – H2 2011                                            GMDHC01756CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Agenus, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 5
Agenus, Inc. Snapshot ............................................................................................................................................................................................. 6
      Agenus, Inc. Overview ....................................................................................................................................................................................... 6
      Key Information .................................................................................................................................................................................................. 6
      Key Facts ........................................................................................................................................................................................................... 6
Agenus, Inc. – Research and Development Overview .............................................................................................................................................. 7
      Key Therapeutic Areas ....................................................................................................................................................................................... 7
Agenus, Inc. – Pipeline Review ................................................................................................................................................................................ 9
      Pipeline Products by Stage of Development ....................................................................................................................................................... 9
      Agenus, Inc. – Pipeline Products Glance...........................................................................................................................................................10
      Agenus, Inc. Clinical Stage Pipeline Products ...................................................................................................................................................10
            Phase II Products/Combination Treatment Modalities .................................................................................................................................10
            Phase I Products/Combination Treatment Modalities ..................................................................................................................................11
Agenus, Inc. – Drug Profiles ....................................................................................................................................................................................12
      HerpV ...............................................................................................................................................................................................................12
            Product Description ....................................................................................................................................................................................12
            Mechanism of Action...................................................................................................................................................................................12
            R&D Progress .............................................................................................................................................................................................12
      Nystatin .............................................................................................................................................................................................................13
            Product Description ....................................................................................................................................................................................13
            Mechanism of Action...................................................................................................................................................................................13
            R&D Progress .............................................................................................................................................................................................13
      Prophage ..........................................................................................................................................................................................................14
            Product Description ....................................................................................................................................................................................14
            Mechanism of Action...................................................................................................................................................................................14
            R&D Progress .............................................................................................................................................................................................14
Agenus, Inc. – Pipeline Analysis ..............................................................................................................................................................................16
      Agenus, Inc. – Pipeline Products by Therapeutic Class .....................................................................................................................................16
      Agenus, Inc. - Pipeline Products By Target .......................................................................................................................................................17
      Agenus, Inc. – Pipeline Products by Route of Administration.............................................................................................................................18
      Agenus, Inc. – Pipeline Products by Molecule Type ..........................................................................................................................................19
Agenus, Inc. – Recent Pipeline Updates .................................................................................................................................................................20
Agenus, Inc. - Dormant Projects ..............................................................................................................................................................................24
Agenus, Inc. - Discontinued Pipeline Products.........................................................................................................................................................25
      Discontinued Pipeline Product Profiles ..............................................................................................................................................................25
            Aroplatin .....................................................................................................................................................................................................25
            ATRA-IV .....................................................................................................................................................................................................25
            AU-801 .......................................................................................................................................................................................................26
            HSPPC-70 ..................................................................................................................................................................................................26
            Zintevir........................................................................................................................................................................................................26
Agenus, Inc. – Company Statement ........................................................................................................................................................................27
Agenus, Inc. – Locations And Subsidiaries ..............................................................................................................................................................30
      Head Office .......................................................................................................................................................................................................30
      Other Locations & Subsidiaries .........................................................................................................................................................................30




Agenus, Inc. – Product Pipeline Review – H2 2011                                                                                                            GMDHC01756CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                 Page(2)
Agenus, Inc. – Product Pipeline Review



Recent Developments .............................................................................................................................................................................................31
           Sep 29, 2008: Antigenics Receives FDA Permission For The Export Of Oncophage To Russia .................................................................31
           Jul 27, 2010: Antigenics Announces Positive Phase I Trial Results Of AG-707 For Treatment Of Genital Herpes.......................................31
           Jun 27, 2011: Agenus’s Herpes Study Results Presented At BIO International Convention Show Robust Immune Response ....................32
           Sep 26, 2011: Agenus Announces Positive Phase I Study Results Of HerpV In Genital Herpes .................................................................33
           Oct 25, 2010: Antigenics Expands Phase II Trial In Glioma.........................................................................................................................34
           Oct 25, 2005: Antigenics Begins Phase I Trial Of Aroplatin In Solid Tumors And B-Cell Lymphoma ...........................................................34
           Nov 24, 2008: Antigenics Announces Final Data From Phase I Investigator-Sponsored Trial Of Oncophage Cancer Vaccine In Glioma ....35
           Nov 21, 2005: Antigenics Initiates Investigator-Sponsored Phase I/II Trial Of Its Oncophage Cancer Vaccine In Glioma ............................36
           May 20, 2010: Antigenics Presents Data On Oncophage Vaccine At International Conference On Brain Tumor Research And Therapy....36
           Oct 18, 2005: Antigenics Initiates Phase 1 Clinical Trial Of AG-707 Therapeutic Vaccine For Genital Herpes.............................................37
           May 18, 2011: Agenus To Present New Data From Prophage G-200 Phase II Recurrent Glioma Trial At ASCO 2011 Annual Meeting ......38
           Nov 16, 2006: Antigenics Presentes Preliminary Data From Phase I/II Investigator-Sponsored Trial Of Its Investigational Cancer Vaccine
           Oncophage At Immunotherapy Task Force Meeting At The Society Of Neuro-Oncology’s Annual Meeting ................................................38
           Nov 12, 1996: Clinical Results Reported On HIV Integrase Inhibitor ...........................................................................................................39
           Aug 12, 2009: Antigenics Begins Enrollment Of Patients In Its Phase II Trial Of Oncophage Cancer Vaccine In Newly Diagnosed Glioma 40
           Mar 12, 2009: Antigenics Receives European Orphan Drug Designation For Oncophage Cancer Vaccine In Brain Cancer .......................40
           Dec 09, 2003: Antigenics Reports Update On Cancer Vaccine Clinical Trials At American Society of Hematology (ASH) Meeting .............41
           Nov 09, 1999: Aronex Pharmaceuticals Receives Orphan Drug Designation For Mesothelioma Indication For Platar (now "Aroplatin")......41
           Apr 08, 2008: Antigenics Announces Approval Of Oncophage For The Treatment OF Intermediate-Risk Kidney Cancer in Russia ............42
           Jun 07, 2006: Antigenics Announces Results From In-Depth Analysis Of Phase III Data Of Oncophage In Kidney Cancer And Provides
           Regulatory Update ......................................................................................................................................................................................42
           Jun 07, 2005: Antigenics’ Oncophage Cancer Vaccine Receives European Orphan Drug Designation For Renal Cell Carcinoma .............43
           Jun 06, 2011: New Data From Phase II Brain Cancer Study With Prophage Series G-200 Shows Improved Overall Survival.....................44
           May 02, 2005: Nature Immunology Publication Supports Immunological Mechanism Of Action Of Antigenics’ Vaccines ............................45
           Jun 01, 2009: Antigenics Presents Positive Oncophage Interim Survival Data At ASCO .............................................................................46
Financial Deals Landscape......................................................................................................................................................................................47
     Agenus, Inc., Deals Summary ...........................................................................................................................................................................47
Agenus, Inc., Pharmaceuticals & Healthcare, Deal Details ......................................................................................................................................48
     Partnerships ......................................................................................................................................................................................................48
           Agenus Enters Into Research Agreement With Memorial Sloan-Kettering Cancer Center ...........................................................................48
     Licensing Agreements .......................................................................................................................................................................................50
           Agenus Enters Into Licensing Agreement With Integrated BioTherapeutics For
								
To top